Skip to main content

Advertisement

SpringerLink
Log in

National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges

  • Position Paper
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

This position paper reviews how the National Bone Health Alliance (NBHA) will execute a project to help assure health professionals of the clinical utility of bone turnover markers; the current clinical approaches concerning osteoporosis and the status and use of bone turnover markers in the USA; the rationale for focusing this effort around two specific bone turnover markers; the need to standardize bone marker sample collection procedures, reference ranges, and bone turnover marker assays in clinical laboratories; and the importance of harmonization for future research of bone turnover markers.

Introduction

Osteoporosis is a major global health problem, with the prevalence and incidence of osteoporosis for at-risk populations estimated to be 44 million Americans. The potential of bone markers as an additional tool for health care professionals to improve patient outcomes and impact morbidity and mortality is crucial in providing better health care and addressing rising health care costs. This need to advance the field of bone turnover markers has been recognized by a number of organizations, including the International Osteoporosis Foundation (IOF), National Osteoporosis Foundation, International Federation of Clinical Chemistry, and Laboratory Medicine (IFCC), and the NBHA.

Methods

This position paper elucidates how this project will standardize bone turnover marker sample collection procedures in the USA, establish a USA reference range for one bone formation (serum procollagen type I N propeptide, s-PINP) and one bone resorption (serum C-terminal telopeptide of type I collagen, s-CTX) marker, and standardize bone turnover marker assays used in clinical laboratories. This effort will allow clinicians from the USA to have confidence in their use of bone turnover markers to help monitor osteoporosis treatment and assess future fracture risk. This project builds on the recommendations of the IOF/IFCC Bone Marker Standards Working Group by developing USA reference standards for s-PINP and s-CTX, the markers identified as most promising for use as reference markers.

Results

The goals of this project will be realized through the NBHA and will include its governmental, academic, for-profit, and non-profit sector stakeholders as well as major academic and commercial laboratories. Upon completion, a parallel effort will be pursued to make bone turnover marker measurements reliable and accepted by all health care professionals for facilitating treatment decisions and ultimately be reimbursed by all health insurance payers.

Conclusions

Successful completion of this project will help assure health professionals from the USA of the clinical utility of bone turnover markers and ties in with the parallel effort of the IOF/IFCC to develop worldwide bone turnover reference ranges.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. NOF (2010) NOF clinician’s guide to prevention and treatment of osteoporosis. NOF, Washington

    Google Scholar 

  2. Schafer AL L, Vittinghoff E, Ramachandran R, Mahmoud N, Bauer DC (2010) Laboratory reproducibility of biochemical markers of bone turnover in clinical practice. Osteoporos Int 21:439–455

    Article  PubMed  Google Scholar 

  3. Vasikaran S, Eastell R, Bruyere O et al (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporosis Int 22(2):391–420

    Article  CAS  Google Scholar 

  4. Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C (2002) Circadian variation in the serum concentration of C-terminal telopeptide of type 1 collagen (serum s-CTX): effects of gender, age, menopausal status, posture, daylight, serum cortisol and fasting. Bone 31:57–61

    Article  PubMed  CAS  Google Scholar 

  5. Clowes JA, Hannon RA, Yap TA, Hoyle NR, Blumsohn A, Eastell R (2002) Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 30:886–890

    Article  PubMed  CAS  Google Scholar 

  6. Rifai N, Cooper GR, Brown WV, Friedewald W, Havel RJ, Myers GL, Warnick GR (2004) Clinical chemistry journal has contributed to progress in lipid and lipoprotein testing for fifty years. Clin Chem 50:1861–1870

    Article  PubMed  CAS  Google Scholar 

  7. Little RR, Rohlfing CL, Sacks DB, National Glycohemoglobin Standardization Program (NGSP) Steering Committee (2011) Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. Clin Chem 57:205–214

    Article  PubMed  CAS  Google Scholar 

  8. Miller WG, Myers GL, Rej R (2006) Why commutability matters. Clin Chem 52:553–554

    Article  PubMed  CAS  Google Scholar 

  9. Miller WG, Myers GL, Gantzer LM, Kahn SE, Schönbrunner ER, Thienpont LM, Bunk DM, Christenson RH, Eckfeldt JH, Lo SF, Nübling CM, Sturgeon CM (2011) Roadmap for harmonization of clinical laboratory measurement procedures. Clin Chem 57:1108–1117

    Article  CAS  Google Scholar 

  10. Clinical and Laboratory Standards Institute (CLSI). www.CLSI.org. Accessed 16 Jan 2012

  11. Serum CrossLaps®ELISA, Immunodiagnostic systems, Inc. technical manual. http://www.idsplc.com. Accessed 16 Jan 2012

  12. CrossLaps/Serum, Roche Diagnostics. Technical manual. http://www.roche.com. Accessed 16 Jan 2012

  13. intact PINP, Immunodiagnostic Systems, Inc. technical manual. http://www.idsplc.com. Accessed 16 Jan 2012

  14. total PINP, Roche Diagnostics technical manual. http://www.roche.com. Accessed 16 Jan 2012

  15. Glover SJ, Garnero P, Naylor K, Rogers A, Eastell R (2008) Establishing a reference range for bone turnover markers in young, healthy women. Bone 42:623–630

    Article  PubMed  CAS  Google Scholar 

  16. Glover S, Gall M, Schoenborn-Kellenberger O, Wagener M, Garnero P, Boonen S, Cauley J, Black D, Delmas P, Eastell R (2009) Establishing a reference interval for bone turnover markers in 637 healthy, young, pre-menopausal women from UK, France, Belgium and the USA. J Bone Miner Res 24:389–397

    Article  PubMed  Google Scholar 

  17. de Papp AE, Bone HG, Caulfield MP, Kagan R, Buinewicz A, Chen E, Rosenberg E, Reitz RE (2007) A cross-sectional study of bone turnover markers in healthy premenopausal women. Bone 40:1222–1230

    Article  PubMed  Google Scholar 

  18. Adami S, Bianchi G, Brandi ML, Giannini S, Ortolani S, Dimunno O, Frediani B, Rossini M (2008) Determinants of bone turnover markers in healthy premenopausal women. Calcif Tissue Int 82:341–347

    Article  PubMed  CAS  Google Scholar 

  19. Cavalier E, Delanaye P (2009) Letter to the editor: Defining a “reference population”: no easy task. JBMR 24:1638

    Article  Google Scholar 

  20. Eastell R, Glover SJ, Gall M, Schoenborn-Kellenberger O, Garnero P, Black D (2009) Defining a “reference population”: no easy task. JBMR 24:1639

    Article  Google Scholar 

  21. Linnet K (1987) Two-stage transformation systems for normalization of reference distributions evaluated. Vlin Vhrm 33:381–386

    CAS  Google Scholar 

  22. Baim S, Miller PD (2009) Perspective: assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res 24:561–573

    Article  PubMed  CAS  Google Scholar 

  23. Keaveny TM, Kopperdahl DL, Melton LJ III, Hoffman PF, Amin S, Riggs BL, Khosla S (2010) Age-dependence of femoral neck strength in white women and men. J Bone Miner Res 25(5):994–1001

    PubMed  Google Scholar 

  24. Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, Griesmacher A, McClung MR, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA, IOF-IFCC Bone Markers Standard Working Group (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22:391–420

    Article  PubMed  CAS  Google Scholar 

  25. Melton LJ III, Khosla S, Atkinson EJ, O’Fallon WM, Riggs BL (1997) Relationship of bone turnover to bone density and fractures. J Bone Miner Res 12:1083–1091

    Article  PubMed  Google Scholar 

  26. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526–1536

    Article  PubMed  CAS  Google Scholar 

  27. Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD (2005) Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 20:1813–1819

    Article  PubMed  Google Scholar 

  28. Garnero P (2000) Markers of bone turnover for the prediction of fracture risk. Osteoporosis Int 11(Suppl 6):S55–S65

    Article  Google Scholar 

  29. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD (1996) Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11:1531–1538

    Article  PubMed  CAS  Google Scholar 

  30. Ivaska KK, Gerdhem P, Vaananen HK, Akesson K, Obrant KJ (2010) Bone turnover markers and prediction of fracture: a prospective follow-up study of 1,040 elderly women for a mean of 9 years. J Bone Miner Res 25:393–403

    Article  PubMed  CAS  Google Scholar 

  31. Bauer DC, Garnero P, Harrison SL, Cauley JA, Eastell R, Ensrud KE, Orwoll E (2009) Osteoporotic fractures in men (MrOs) Research Group. Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOs Study. J Bone Miner Res 24(12):2032–2038

    Article  PubMed  CAS  Google Scholar 

  32. Rosen HN, Moses AC, Garber J, Iloputaife ID, Ross DS, Lee SL, Greenspan SL (2000) Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66:100–103

    Article  PubMed  CAS  Google Scholar 

  33. Recker R, Stakkestad JA, Chesnut CH III, Christiansen C, Skag A, Hoiseth A, Ettinger M, Mahoney P, Schimmer RC, Delmas PD (2004) Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34:89–93

    Article  Google Scholar 

  34. Papapolpous S, Schimmer RC (2007) Changes in bone remodeling and anti-fracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Ann Rheum Dis 66(7):853–858

    Google Scholar 

  35. Chesnut CH III, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249

    Article  CAS  Google Scholar 

  36. Christiansen C, Riis BJ, Rodbro P (1987) Prediction of rapid bone loss in postmenopausal women. Lancet 1:1105–1108

    Article  PubMed  CAS  Google Scholar 

  37. Lenora J, Ivaska KK, Obrant KJ, Gerdhem P (2007) Prediction of bone loss using biochemical markers of bone turnover. Osteoporos Int 18:1297–1305

    Article  PubMed  CAS  Google Scholar 

  38. Rogers A, Hannon RA, Eastell R (2000) Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res 15:1398–1404

    Article  PubMed  CAS  Google Scholar 

  39. Greenspan SL, Resnick NM, Parker RA (2005) Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 90:2762–2767

    Article  PubMed  CAS  Google Scholar 

  40. Hannon RA, Bluhmson A, Naylor KE, Eastell R (1998) Response of biochemical markers of bone turnover to hormone replacement therapy. J Bone Miner Res 13:1124–1133

    Article  PubMed  CAS  Google Scholar 

  41. Kim SW, Park DJ, Park KS, Kim SY, Cho BY, Lee HK, Shin CS (2005) Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. Endocr J 52:667–674

    Article  PubMed  CAS  Google Scholar 

  42. Ravn P, Clemmesen B, Christiansen C (1999) Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24:237–244

    Article  PubMed  CAS  Google Scholar 

  43. Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, Yates AJ, Bjarnason NH, Christiansen C (1999) Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84:2363–2368

    Article  PubMed  CAS  Google Scholar 

  44. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB (1998) Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 13:1431–1438

    Article  PubMed  CAS  Google Scholar 

  45. Greenspan SL, Rosen HN, Parker RA (2000) Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab 85:3537–3540

    Article  PubMed  CAS  Google Scholar 

  46. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051–1056

    Article  PubMed  CAS  Google Scholar 

  47. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250–1258

    Article  PubMed  Google Scholar 

  48. Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D et al (2004) Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34:344–351

    Article  PubMed  CAS  Google Scholar 

  49. Reginster JY, Collette J, Neuprez A, Zegels B, Deroisy R, Bruyere O (2008) Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone 42:832–836

    Article  PubMed  CAS  Google Scholar 

  50. Tsujimoto M, Chen P, Miyauchi A, Sowa H, Krege JH (2011) PINP as an aid for monitoring patients treated with teriparatide. Bone 48:798–803

    Article  PubMed  CAS  Google Scholar 

  51. Porter D, Pienowski D, Monier-Faugere MC, Mallluche H (2012) Difference in bone quality between high versus low turnover renal osteodystrophy. JASN (in press)

  52. Nickolas T, Cremers S, Zhang A, Stein E, Cohen A, Chauncey R, Nikkel L, Liu X, Boutroy S, Yin M, Staron R, Leonard M, McMahon D, Dworakowski E, and Shane E (2012) Biochemical markers of bone turnover discriminate fracture status in patients with pre-dialysis chronic kidney disease. JASN (in press)

  53. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. University of California, San Francisco, USA

    D. Bauer

  2. Eli Lilly and Co., Inc., Indianapolis, USA

    J. Krege

  3. University of California Davis Health System, Sacramento, USA

    N. Lane

  4. Pacific Biomarkers, Seattle, USA

    E. Leary

  5. Amgen, Thousand Oaks, USA

    C. Libanati

  6. Colorado Center for Bone Research, Lakewood, USA

    P. Miller

  7. American Association for Clinical Chemistry, Washington, USA

    G. Myers

  8. Cedars-Sinai Medical Center, Los Angeles, USA

    S. Silverman

  9. Centers for Disease Control and Prevention, Atlanta, USA

    H. W. Vesper

  10. National Bone Health Alliance, Washington, USA

    D. Lee

  11. Roche Diagnostics, Indianapolis, USA

    M. Payette

  12. National Osteoporosis Foundation, Washington, USA

    S. Randall

Authors
  1. D. Bauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Krege
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Lane
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Leary
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Libanati
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Myers
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. Silverman
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H. W. Vesper
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. D. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M. Payette
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. S. Randall
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Bauer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bauer, D., Krege, J., Lane, N. et al. National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int 23, 2425–2433 (2012). https://doi.org/10.1007/s00198-012-2049-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-012-2049-z

Keywords

Search

Navigation